Please assess the completion status of the following clinical trial:

Trial Title: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or biopsy proven adenocarcinoma of the pancreas. Cytology is acceptable if histology cannot be obtained.~2. Newly diagnosed non-metastatic PC judged by tumor board to be feasible for SBRT~3. Completed at least 6 weeks of chemotherapy consisting of FOLFIRINOX, mFOLFIRINOX, or a gemcitabine-based doublet regimen prior to start of SBRT~4. Remain non-metastatic as confirmed by a CT scan at screening.~5. Female or male subjects ≥ 18 years of age~6. ECOG performance status of 0-2~7. Adequate end-organ function~Exclusion Criteria:~1. Subjects with documented metastatic disease~2. First-line chemotherapy other than FOLFIRINOX, mFOLFIRINOX, and/or a gemcitabine-based doublet regimen~3. Prior abdominal RT with substantial overlap in radiation fields~4. Subjects not recovered/controlled from treatment-related toxicities~5. Uncontrolled malignancy other than PC~6. Uncontrolled gastric or duodenal ulcer disease within 30 days of dosing~7. Visible invasion of bulky tumor into the lumen of the bowel or stomach on endoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A Active GC4711 (Type: EXPERIMENTAL): None
- Arm B Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).